Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

In the U.S., Dupixent remains the leader in new to brand prescription share across ... HD uptake starting in the second half of this year. Libtayo became Regeneron's latest blockbuster product ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Libtayo sales are being driven by growth in ... The drug has been approved under the brand name Ordspono. Investors will also look for key pipeline updates from Regeneron apart from the top ...

Fast-casual Ohio-based US restaurant brand City BBQ has formed a partnership with customer data platform Bikky to drive ...

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

Taking control of your brand can mean the difference between an unfulfilling job and a rewarding career. But how can you persuade others to take the reinvented you seriously? The author presents a ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...